We are focused on the discovery, development and
commercialization of first-in-class treatments for
cancer. 

Leveraging the body’s
natural elements

VBL’s clinical pipeline is based on two platform technologies that enhance natural physiologic and genetic regulatory elements.

VTS Platform for cancer
Lecinoxoids Platform 

 

Promising therapies

Our lead candidate is VB-111, a gene-based biologic agent for solid tumor indications. VB-111 pivotal Phase 3 GLOBE trial in rGBM is ongoing under a special protocol assessment granted by the FDA.

GBM
Thyroid cancer
Ovarian cancer